Estrogen & Progesterone Effects on Orthostatic Tolerance

雌激素

基本信息

  • 批准号:
    6895431
  • 负责人:
  • 金额:
    $ 33.68万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2003
  • 资助国家:
    美国
  • 起止时间:
    2003-07-01 至 2007-06-14
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Orthostastic intolerance is a dysfunction of the cardiovascular system that affects primarily young, healthy women. Diminished circulating blood volume and low peripheral resistance are primary mechanisms for orthostatic intolerance. Estrogen and progesterone modulate both plasma volume (PV) and peripheral vascular resistance (PVR). The purpose of this study is to compare PV regulation, PVR and orthostatic tolerance in women under four different hormonal conditions: when estrogen and progesterone are suppressed; when estrogen is elevated; when progesterone is elevated, and when progesterone and estrogen are elevated. The Specific Aims are: 1) To determine estrogen and progesterone modulation of extracellular fluid and protein distribution, and renal mechanisms controlling water retention. Plasma protein changes alter the colloid osmotic pressure gradient across capillaries and selectively enhance or reduce plasma volume. We hypothesize that estrogen acts on vessels to reduce vascular permeability to proteins, thereby reducing protein and fluid movement out of the vasculature and increasing PV. Moreover, we will test the hypothesis that estrogen and progesterone increase total extracellular fluid volume (ECFV) associated with renin-angiotensin-aldosterone system (RAAS)-mediated renal adjustments. Thus cardiovascular adjustments to postural changes may be improved when estrogen is elevated due to greater fluid retention and due to selective fluid retention in the plasma. We also hypothesize that PV expansion is the consequence of ECFV expansion when progesterone is increased concomitant with estrogen. High progesterone alone may reduce PV both by reducing colloid osmotic pressure gradient across capillaries and by attenuating aldosterone actions on the kidney, reducing water retention, and thus extracellular fluid and plasma volumes. 2) To test the hypothesis that estrogen-related reductions in PVR response to posture changes contribute to orthostatic intolerance in women, and progesterone antagonizes these estrogen mediated changes in PVR, helping to maintain orthostatic tolerance. These studies will define the impact of estrogen and progesterone on the interaction between blood volume and vascular resistance during orthostatic challenges, and thus may improve treatment of orthostatic intolerance in women.
描述(由申请人提供):矫形不耐受是一种主要影响年轻健康女性的心血管系统功能障碍。循环血容量减少和外周抵抗力低是直立性不耐受的主要机制。雌激素和孕激素调节血浆容量(PV)和外周血管阻力(PVR)。本研究的目的是比较四种不同激素条件下女性的PV调节、PVR和直立耐受性:当雌激素和孕激素被抑制时;当雌激素升高时;当黄体酮升高,当黄体酮和雌激素升高。具体目的是:1)确定雌激素和孕激素对细胞外液和蛋白质分布的调节,以及肾脏控制水潴留的机制。血浆蛋白的改变改变了毛细血管间的胶体渗透压梯度,选择性地增加或减少了血浆体积。我们假设雌激素作用于血管,降低血管对蛋白质的通透性,从而减少蛋白质和液体从脉管系统中流出,增加PV。此外,我们将验证雌激素和孕激素增加与肾素-血管紧张素-醛固酮系统(RAAS)介导的肾脏调节相关的总细胞外液容量(ECFV)的假设。因此,当雌激素升高时,由于更大的液体潴留和血浆中的选择性液体潴留,心血管对体位变化的调节可能得到改善。我们还假设,当孕激素与雌激素同时增加时,PV扩张是ECFV扩张的结果。单独高孕酮可通过降低毛细血管上的胶体渗透压梯度和减弱醛固酮对肾脏的作用,减少水潴留,从而减少细胞外液和血浆体积,从而降低PV。2)验证雌激素相关的PVR对体位改变反应的降低导致女性站立不耐受,孕激素拮抗这些雌激素介导的PVR变化,帮助维持站立耐受的假设。这些研究将确定雌激素和孕激素对直立挑战时血容量和血管阻力之间相互作用的影响,从而可能改善女性直立不耐受的治疗。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

NINA STACHENFELD其他文献

NINA STACHENFELD的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('NINA STACHENFELD', 18)}}的其他基金

Cardiometabolic effects of gender-affirming hormone therapy in transgender adolescents
性别肯定激素治疗对跨性别青少年的心脏代谢影响
  • 批准号:
    10526022
  • 财政年份:
    2022
  • 资助金额:
    $ 33.68万
  • 项目类别:
Cardiometabolic effects of gender-affirming hormone therapy in transgender adolescents
性别肯定激素治疗对跨性别青少年的心脏代谢影响
  • 批准号:
    10675704
  • 财政年份:
    2022
  • 资助金额:
    $ 33.68万
  • 项目类别:
Phytoestrogens, insulin resistance and endothelial function
植物雌激素、胰岛素抵抗和内皮功能
  • 批准号:
    8174263
  • 财政年份:
    2011
  • 资助金额:
    $ 33.68万
  • 项目类别:
Phytoestrogens, insulin resistance and endothelial function
植物雌激素、胰岛素抵抗和内皮功能
  • 批准号:
    8304911
  • 财政年份:
    2011
  • 资助金额:
    $ 33.68万
  • 项目类别:
Compromised microcirculation in women with Polycystic Ovary Syndrome
多囊卵巢综合症女性的微循环受损
  • 批准号:
    7903860
  • 财政年份:
    2009
  • 资助金额:
    $ 33.68万
  • 项目类别:
Compromised microcirculation in women with Polycystic Ovary Syndrome
多囊卵巢综合症女性的微循环受损
  • 批准号:
    7742059
  • 财政年份:
    2009
  • 资助金额:
    $ 33.68万
  • 项目类别:
Estrogen & Progesterone Effects on Orthostatic Tolerance
雌激素
  • 批准号:
    7489666
  • 财政年份:
    2003
  • 资助金额:
    $ 33.68万
  • 项目类别:
Estrogen & Progesterone Effects on Orthostatic Tolerance
雌激素
  • 批准号:
    7259773
  • 财政年份:
    2003
  • 资助金额:
    $ 33.68万
  • 项目类别:
Estrogen & Progesterone Effects on Orthostatic Tolerance
雌激素
  • 批准号:
    6759457
  • 财政年份:
    2003
  • 资助金额:
    $ 33.68万
  • 项目类别:
Estrogen & Progesterone Effects on Orthostatic Tolerance
雌激素
  • 批准号:
    6680170
  • 财政年份:
    2003
  • 资助金额:
    $ 33.68万
  • 项目类别:

相似海外基金

Atrial Natriuretic Peptide and Regulation of Cardiometabolic Health: A Genotype-Guided Human Physiological Study
心钠素和心脏代谢健康的调节:基因型引导的人类生理学研究
  • 批准号:
    10627996
  • 财政年份:
    2022
  • 资助金额:
    $ 33.68万
  • 项目类别:
Atrial Natriuretic Peptide and Regulation of Cardiometabolic Health: A Genotype-Guided Human Physiological Study
心钠素和心脏代谢健康的调节:基因型引导的人类生理学研究
  • 批准号:
    10419574
  • 财政年份:
    2022
  • 资助金额:
    $ 33.68万
  • 项目类别:
Mitochondria-mediated effects and therapeutic potential of Atrial Natriuretic Peptide in salt-sensitive hypertension
心房钠尿肽在盐敏感性高血压中的线粒体介导作用和治疗潜力
  • 批准号:
    10676800
  • 财政年份:
    2020
  • 资助金额:
    $ 33.68万
  • 项目类别:
Mitochondria-mediated effects and therapeutic potential of Atrial Natriuretic Peptide in salt-sensitive hypertension
心房钠尿肽在盐敏感性高血压中的线粒体介导作用和治疗潜力
  • 批准号:
    10442162
  • 财政年份:
    2020
  • 资助金额:
    $ 33.68万
  • 项目类别:
Mitochondria-Mediated Effects and Therapeutic Potential of Atrial Natriuretic Peptide in Salt-Sensitive Hypertension Diversity Supplement
盐敏感性高血压多样性补充剂中心房钠尿肽的线粒体介导作用和治疗潜力
  • 批准号:
    10337412
  • 财政年份:
    2020
  • 资助金额:
    $ 33.68万
  • 项目类别:
Mitochondria-mediated effects and therapeutic potential of Atrial Natriuretic Peptide in salt-sensitive hypertension
心房钠尿肽在盐敏感性高血压中的线粒体介导作用和治疗潜力
  • 批准号:
    10472035
  • 财政年份:
    2020
  • 资助金额:
    $ 33.68万
  • 项目类别:
Development of a high-precision diagnostic method for heart failure utilizing abnormal biosynthesis of beta-atrial natriuretic peptide in the failing heart
利用衰竭心脏中β-心房钠尿肽的异常生物合成开发心力衰竭的高精度诊断方法
  • 批准号:
    20K08414
  • 财政年份:
    2020
  • 资助金额:
    $ 33.68万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Atrial natriuretic peptide induces peroxisome proliferator
心钠素诱导过氧化物酶体增殖
  • 批准号:
    15K10206
  • 财政年份:
    2015
  • 资助金额:
    $ 33.68万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Atrial natriuretic peptide prevents cancer metastasis through vascular endothelial cells.
心房钠尿肽可防止癌症通过血管内皮细胞转移。
  • 批准号:
    26461393
  • 财政年份:
    2014
  • 资助金额:
    $ 33.68万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Novel strategy for heart failure treatment with recombinant atrial natriuretic peptide-induced cardiac progenitor cells
重组心钠素诱导的心脏祖细胞治疗心力衰竭的新策略
  • 批准号:
    25461069
  • 财政年份:
    2013
  • 资助金额:
    $ 33.68万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了